225Ac-PSMA is one of the novel theragnostic alpha endoradiotherapy agents under investigation for salvage therapy in metastatic castration resistant prostate cancer (mCRPC). We present a case of hormone naïve patient with high-volume metastatic, symptomatic prostate cancer involving the lungs. The ...
2019;49(4):313–25. Article PubMed Google Scholar Kratochwil C, Haberkorn U, Giesel FL. 225Ac-PSMA-617 for therapy of prostate cancer. Semin Nucl Med. 2020a;50(2):133–40. Article PubMed Google Scholar Kratochwil C, et al. Patients resistant against PSMA-targeting α-radiation ...
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J. Nucl. Med. 2016, 57, 1941–1944. [CrossRef] [PubMed] 9. Morgenstern, A.; Bruchertseifer, F.; Apostolidis, C. Bismuth-213 and actinium-225—Generator performance and evolving ...